LungMate-014
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
- NCT05891080 ↗
- Not yet recruiting
- Shanghai Pulmonary Hospital, Shanghai, China
- Focused
We haven't built an HCP commentary report on LungMate-014 (toripalimab, JS004 and 3 more in Stage III Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LungMate-014 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
- Phase
- Phase 2
- Status
- Not yet recruiting
- Conditions
- Stage III Non-small Cell Lung Cancer
- Interventions
- Toripalimab; JS004; Pemetrexed; Nab-paclitaxel; Carboplatin; Surgery
- Arms
- Safety run-in arm · Experimental
- JS004 arm · Experimental
- Control arm · Active comparator
- Enrollment
- 124 (estimated)
- Primary outcomes
- Pathologic complete response (PCR) rate
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Start
- Jul 1, 2023 (estimated)
- Primary completion
- Jul 1, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05891080 · updated Jun 6, 2023